RET and neoplasm: While selpercatinib has demonstrated efficacy in treating RET fusion-positive tumours, vigilant monitoring and management of adverse events, particularly those related to laboratory abnormalities and serious reactions, are pivotal components of patient care during selpercatinib therapy.